

CAPN6 RABBIT PAB

货号: S210181

产品全名: CAPN6 兔多抗

基因符号: CANPX; CAPNX; CalpM; DJ914P14.1

UNIPROT ID: Q9Y6Q1 (Gene Accession - BC000730)

背景: Calpains are ubiquitous, well-conserved family of calcium-dependent, cysteine proteases. The calpain proteins are heterodimers consisting of an invariant small subunit and variable large subunits. The large subunit possesses a cysteine protease domain, and both subunits possess calcium-binding domains. Calpains have been implicated in neurodegenerative processes, as their activation can be triggered by calcium influx and oxidative stress. The protein encoded by this gene is highly expressed in the placenta. Its C-terminal region lacks any homology to the calmodulin-like domain of other calpains. The protein lacks critical active site residues and thus is suggested to be proteolytically inactive. The protein may play a role in tumor formation by inhibiting apoptosis and promoting angiogenesis.

抗原: Fusion protein of human CAPN6

经过测试的应用: ELISA, WB, IHC

推荐稀释比: IHC: 50-100;WB: 500-2000;ELISA: 5000-10000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse, Rat


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction, Cell Biology


储存和运输: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 210181 (CAPN6 Antibody) at a dilution of 1/70 (Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 210181 (Anti-CAPN6 Antibody) at dilution 1/70.



Gel: 8%SDS-PAGE, Lysate: 40 µg;

Lane 1-2: TM4 and NIH/3T3 cell lysates;

Primary antibody: 210181 (CAPN6 Antibody) at dilution 1/500;

Secondary antibody: HRP-conjugated Goat anti rabbit IgG at 1/5000 dilution;

Exposure time: 15 seconds



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
